9MW5211 / Mabwell (Shanghai) Biosci - LARVOL DELTA

Mabwell (Shanghai) Bioscience…has received the Approval Notice for Clinical Trials of Drugs from the National Medical Products Administration ('NMPA'), pursuant to which the clinical trial application for 9MW5211 injection for the indication of primary biliary cholangitis ('PBC') has been approved (HKEXnews)

New trial • Primary Biliary Cholangitis

Mabwell (Shanghai) Bioscience…has received the Approval Notice for Clinical Trials of Drugs from the National Medical Products Administration ('NMPA'), pursuant to which the clinical trial application for 9MW5211 injection for the indication of vitiligo has been approved (HKEXnews)

New trial • Immunology • Vitiligo

Mabwell (Shanghai) Bioscience...has received the Approval Notice for Clinical Trials of Drugs from the National Medical Products Administration ('NMPA'), pursuant to which the clinical trial application for 9MW5211 injection for the treatment of multiple sclerosis ('MS') has been approved (HKEXnews) - "The Company is also actively advancing clinical trial applications for multiple other indications, and clinical trial applications for some of those indications have been accepted for review by the NMPA."

New trial • Multiple Sclerosis

Mabwell…announced that its independently developed innovative antibody drug 9MW5211 has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for inflammatory bowel disease (IBD) (PRNewswire)

New trial • Inflammatory Bowel Disease

Mabwell…announced that the Investigational New Drug (IND) application for 9MW5211, its independently developed novel antibody, has received clearance from the U.S. Food and Drug Administration (FDA) to conduct clinical studies for the treatment of inflammatory bowel disease (IBD) (PRNewswire) - "Clinical trial applications for multiple indications including IBD and multiple sclerosis (MS) have been accepted for review by the National Medical Products Administration (NMPA) of China. 9MW5211 is the world's first clinical-stage drug candidate for its target."

IND • New trial • Inflammatory Bowel Disease • Multiple Sclerosis

World's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Application (The Manila Times)

IND • Inflammatory Bowel Disease